GP1-1 drugs, originally developed as a treatment for diabetes, are shaking up some sectors. Developments surrounding the drugs, also popularly used for weight loss, have been disrupting anything from owners of dialysis centers to bariatric surgery providers and the food industry. But one investment advisor, Brian Krawez, president of Scharf Investments, says there are opportunities.
Krawez said the selloff in one consumer staple stock is "unwarranted": Unilever . Its shares have been down 12% since the end of July on GLP-1 fears, he noted on Tuesday. "We think it's not that exposed — 6% of its sales are U.S. food, and so we just think it's kind of a big throw in the bathwater," he told CNBC's " Street Signs Asia " on Tuesday.
เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม: